Related Experiment Video
Updated: Jul 10, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Risperidone Serum Levels in Depression: Insights From a Retrospective Therapeutic Drug Monitoring Study
Melike Kucukkarapinar1, Kohler Meike1,2, Weber Heike1
1Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg.
Therapeutic drug monitoring for risperidone in depression requires different reference ranges than those for schizophrenia. A preliminary range of 10-30 ng/mL is suggested for effective treatment of depressive disorders.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Chemistry
Background:
- Risperidone is an adjunctive treatment for treatment-resistant depression.
- Current therapeutic drug monitoring guidelines lack established risperidone reference ranges for depressive disorders.
Purpose of the Study:
- To compare risperidone active moiety (AM) serum concentrations between schizophrenia spectrum disorders (SSD) and depression patients.
- To establish preliminary therapeutic reference ranges for risperidone in depression.
Main Methods:
- Retrospective observational study of 401 inpatients administered risperidone (2015-2020).
- Comparison of AM serum concentrations (risperidone + 9-hydroxyrisperidone) between SSD and depression cohorts.
- Assessment of AM serum levels and treatment efficacy using the Clinical Global Impression-Improvement scale in the depression cohort.
Main Results:
- AM serum concentration was significantly higher in patients with SSD compared to those with depression (P < 0.001).
- 50% of depression patients achieved successful treatment with lower AM serum concentrations than typically used for SSD.
Conclusions:
- Established therapeutic reference ranges for SSD are not applicable to depression treatment.
- A preliminary therapeutic reference range of 10-30 ng/mL is suggested for risperidone in depressive disorders.
Related Concept Videos
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring: Affecting Factors
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Overview and Classification
Psychosis: Goals of Pharmacotherapy